Cargando…

Tumor‐immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas

Immunotherapy is a new anti‐cancer treatment option, showing promising results in clinical trials. To investigate potential immune biomarkers in esophageal adenocarcinoma (EAC), we explored immune landscape patterns in the tumor microenvironment before and after neoadjuvant chemoradiation (nCRT). Se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soeratram, Tanya TD, Creemers, Aafke, Meijer, Sybren L, de Boer, Onno J, Vos, Wim, Hooijer, Gerrit KJ, van Berge Henegouwen, Mark I, Hulshof, Maarten CCM, Bergman, Jacques JGHM, Lei, Ming, Bijlsma, Maarten F, Ylstra, Bauke, van Grieken, Nicole CT, van Laarhoven, Hanneke WM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299918/ https://www.ncbi.nlm.nih.gov/pubmed/34743329 http://dx.doi.org/10.1002/path.5832

Ejemplares similares

Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma
por: Haj Mohammad, Nadia, et al.
Publicado: (2014)

Chemoradiation induces epithelial‐to‐mesenchymal transition in esophageal adenocarcinoma
por: Steins, Anne, et al.
Publicado: (2019)

The dynamics of HER2 status in esophageal adenocarcinoma
por: Creemers, Aafke, et al.
Publicado: (2018)

Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer
por: Dings, Mark P.G., et al.
Publicado: (2022)

FOXO transcriptional activity is associated with response to chemoradiation in EAC
por: Creemers, A., et al.
Publicado: (2022)

A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas
por: Creemers, Aafke, et al.
Publicado: (2018)

Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition
por: van den Ende, Tom, et al.
Publicado: (2023)

Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma
por: Ebbing, Eva A., et al.
Publicado: (2019)

Influence of body composition and muscle strength on outcomes after multimodal oesophageal cancer treatment
por: Hagens, Eliza R.C., et al.
Publicado: (2020)

The Cellular Origins of Cancer-Associated Fibroblasts and Their Opposing Contributions to Pancreatic Cancer Growth
por: Manoukian, Paul, et al.
Publicado: (2021)

ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3
por: Ebbing, Eva A., et al.
Publicado: (2016)

A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX
por: Stroes, Charlotte I., et al.
Publicado: (2021)

Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)
por: Schokker, Sandor, et al.
Publicado: (2019)

Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: A population‐based study
por: Pape, Marieke, et al.
Publicado: (2022)

Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer
por: van Velzen, Merel J. M., et al.
Publicado: (2022)

On the Receiving End of Autonomy and Law
por: van Laarhoven, Hanneke W. M., et al.
Publicado: (2017)

Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis
por: Creemers, A., et al.
Publicado: (2017)

Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer
por: Veenstra, Veronique L., et al.
Publicado: (2018)

The impact of the COVID-19 pandemic on the diagnosis, stage, and treatment of esophagogastric cancer
por: Doeve, Benthe H., et al.
Publicado: (2023)

A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT)
por: Stroes, Charlotte I, et al.
Publicado: (2022)

Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma
por: Strijker, Marin, et al.
Publicado: (2019)

Radiotherapy is the Preferred Primary Tumor Treatment in Oligometastatic Prostate Cancer
por: van Moorselaar, R. Jeroen A., et al.
Publicado: (2022)

Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis
por: van den Ende, Tom, et al.
Publicado: (2019)

Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: van Mackelenbergh, Madelaine G., et al.
Publicado: (2019)

(18)F-FDG PET-CT after Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients to Optimize Surgical Decision Making
por: Anderegg, Maarten C. J., et al.
Publicado: (2015)

PD-1 The impact of COVID-19 on diagnosis, stage and treatment of esophageal and gastric cancer
por: Bakx, J., et al.
Publicado: (2022)

Combined Expression of Plasma Thrombospondin‐2 and CA19‐9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach
por: Le Large, Tessa Y.S., et al.
Publicado: (2020)

Quantifying intrafractional gastric motion using auto‐segmentation on MRI: Deformation and respiratory‐induced displacement compared
por: Driever, Theo, et al.
Publicado: (2022)

Feasibility of using optical coherence tomography to detect radiation-induced fibrosis and residual cancer extent after neoadjuvant chemo-radiation therapy: an ex vivo study
por: Jelvehgaran, Pouya, et al.
Publicado: (2018)

Microscopic tumor spread beyond (echo)endoscopically determined tumor borders in esophageal cancer
por: Machiels, Melanie, et al.
Publicado: (2019)

The effect of on-line position correction on the dose distribution in focal radiotherapy for bladder cancer
por: van Rooijen, Dominique C, et al.
Publicado: (2009)

Independent position correction on tumor and lymph nodes; consequences for bladder cancer irradiation with two combined IMRT plans
por: van Rooijen, Dominique C, et al.
Publicado: (2010)

Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials
por: Biesma, Hedde D., et al.
Publicado: (2022)

Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract
por: Damhofer, Helene, et al.
Publicado: (2015)

Macrophage-secreted MMP9 induces mesenchymal transition in pancreatic cancer cells via PAR1 activation
por: Tekin, Cansu, et al.
Publicado: (2020)

The success of anti-PD-1 with chemotherapy for esophageal squamous cell carcinoma
por: van Laarhoven, Hanneke W.M., et al.
Publicado: (2023)

SPOTlight on GLOW
por: Derks, Sarah, et al.
Publicado: (2023)

Gastric cancers of Western European and African patients show different patterns of genomic instability
por: Buffart, Tineke E, et al.
Publicado: (2011)

Patched-2 functions to limit Patched-1 deficient skin cancer growth
por: Veenstra, Veronique L., et al.
Publicado: (2018)

Pathological validation and prognostic potential of quantitative MRI in the characterization of pancreas cancer: preliminary experience
por: Klaassen, Remy, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sl3495d3170f9si93i56kb3qr7